05:47 AM EDT, 09/22/2026 (MT Newswires) -- Roche's (RO.SW) experimental weight-management drug enicepatide met the primary endpoints of a mid-stage study by helping patients reduce their blood sugar and body weight. The CT-388-104 phase 2 clinical trial assessed the efficacy of the once-weekly dual GLP-1/GIP receptor agonist in adults with type 2 diabetes and overweight or obesity. The study showed that patients administered with 24-milligram enicepatide, the highest titrated dose, showed a 2.65% reduction in blood sugar levels and a mean weight loss of 15.5% after 48 weeks, according to a Tuesday release. Additionally, 90% of patients in the 24-mg group achieved a blood sugar level of less than or equal to 6.5%, while 62% reached normal blood glucose levels. The safety and tolerability profile remained in line with other established incretin-based therapies. "The totality of data positions enicepatide, a unique dually biased GLP-1/GIP receptor agonist, as a differentiated molecule designed for potentially greater efficacy with a favorable safety profile," the company said while announcing the trial's results. Roche is conducting a late-stage development program for enicepatide, including two ongoing phase 3 trials in chronic weight management, with plans for a phase 3 glycemic-control program and cardiovascular outcomes studies in the first half of 2027. Roche's shares were slightly lower during early trading in Zürich.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.